Drug Profile
Cositecan
Alternative Names: BNP 1350; BNP Karenitecin; DB 172; Karenitecin; UNII-24R60NVC41Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioNumerik Pharmaceuticals
- Developer Alliance for Clinical Trials in Oncology; Baylor College of Medicine; BioNumerik Pharmaceuticals; Pediatric Brain Tumor Consortium
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Ovarian cancer
- Phase II Brain cancer; Malignant melanoma; Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease) in USA (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In adolescents, In children, Late-stage disease) in USA (IV, Infusion)